the call then for our joining go screening. into call. more the Thanks, Carrie. afternoon, at call a will progress outlook detailed And third and provide then third I top the quarter XXXX. will over AmirAli and in and thank Mike will more for financials of line therapy quarter and selection update for detail finally, XXXX our Good turn to an our on MRD. earnings remainder look start with our you I today our off results for on
Day, a liquid we for lives In with comprehensive a our suite Investor tests, in X. are where Slide continuum our of the Guardant. opportunities selection, opportunity we of of biopsy encourage hosted across on where with we leader are who have early I screening ahead far decade was in of our wasn't look going. to on September, and attend to anyone we the on access able Investors replay It transforming vision MRD section to over shared care. to Starting past Day patient Guardant and we the great how inaugural strong website. pipeline long-term the therapy is a reflect our Investor come our
We scratching a believe are surface massive of what opportunity the front of just we is us. in
patient patients demonstrate what a I reach our to of always call has by commitment our We heart to newest our do. look story patient to Our impact the lives we more forward grow the start at our across off product, Shield. sharing globe. today of continuing will to test, To impact for been the
prioritized to colonoscopy surgery months colorectal away, initial After receiving started She been She procedure this colonoscopy primary of position position. had she healthy cancer. was will and a year, LVP visited Though an she the our she for a to a was late cancer colonoscopy. Shield test, her right XXs treatment, in at this their that added abnormality, she care was the few by to from was X a and colon. Earlier unscreened of just reflected results The Stage Shield, our hesitant determined visit, followed test annual physician resistant again. chemotherapy Shield proposed to had The order bloodwork. which her of portion surgery getting a result which colorectal letter colonoscopy. done. receiving woman Her remove a
progress workflow. past use delivering fall. a This through and patients patient preference this collective their as exist. others these [ of today to face making as many The we position the screening powerful the can. like card we results wedding early, commitment With to cancer why of positive help who our is and her are of our share is compliance able of of example was we reflect who just ease this funds ] her to increase millions we cancer the year, participate will on in story in and this Serving mission the
to Turning Slide X. on performance line top
was third are quarter. revenue, solid to Precision with We in the million. increased pleased XX% our $XXX with Oncology revenue quarter growing This which another results this XX% year by growth driven
a We our growth number see selection the over long drive to of continue to in therapy core tailwinds with strength business term.
Slide third test strong tests Clinical during across growth reached a Oncology combined from Clinical was from during growth record of tests, products X. increase robust driven delivered of by to We platform. quarter. XX,XXX our the strong Turning by XX% the commercial supported quarter volume number quarter. prior the contributions Precision key with an a year
delivered biopharma, For we X,XXX XX% increasing year-over-year. tests,
Slide to Turning X.
the Looking from quarter. highlights closely more some the at third of
We growth strength across continue GuardantXXX solid year of the United TissueNext. half oncologists which core our are ordering nearly to benefit now of from clinical quarter year-over-year volume tailwinds and selection a GuardantXXX every month, the in States highlights seen with therapy of earlier Notably, the test in another business.
by with As mutation following for demand. the approvals CDx GuardantXXX positive approval patients, breast spike in we and QX, a ESRX QX new is volumes pent-up in fueled saw typical
therefore, expect this which we breast in volume we from That had sequentially continued QX, in QX backlog and breast the In this significantly through still to test increased said, a contribution indication. see less strong we growth year-over-year, QX. than worked in in had cancer and quarter,
Flatiron oncology CGP this EMR underway, on the in providers of of focused providing X top States. the test commercial in the integrating Our remains and United within team best the infrastructure week, are the Last process With we in our EMR. experience. integration customer announced oncology investing our we
in accounts. reduce XXX integrations oncologists be the providers in to These approximately end collectively X/X by all the to these and XX%. of year, oncology time we practices integrated represent of are expected ordering by the Notably, fully expect over country
in gains, expect efficiency we in an and benefits these XXXX. partnerships experience ordering to contribute customer the to addition to In volume uplift
contribution MRD of also another from for with Reveal. record growing quarter Guardant We seeing are volumes
on Reveal by year. biopsy to with upgrade are We smart end track this liquid of
geographies Investor we contribution expanding are seeing and globally. our other into increasing we shared an Day, at from labs As are
saw in to Garden This CDP interest technology this good to of Laboratory awarded quarter, NHS cancer powered expression the thousands momentum, Royal across by was the potentially particularly the non-small of country. cell Marson making Europe for an launch England, we as in lung accessible patients
for progress in cancer regulatory Japan in CDx in approval This follows the with ENHERTU of GuardantXXX also for the reimbursement clinical diagnostic recent mutations. lung use recent of received Japan. patients launches our with non-small companion September, biopharma national CDx We a and Asia became of in of as to July. GuardantXXX which for China assays ENHERTU GuardantXXX are in use at treatment end for making early good In the effective cell approval Japan,
Japan largest We market expansion portfolio. our opportunity represents are really the in opportunity within excited as currently this about the
While portion markets a relatively next over has international from the expect these revenue historically year. we of core been volume, small significant growth
X. with Moving to provide tailwinds in the In see we Starting continue in breakthroughs clinical selection. near third on payer term. for business the quarter, therapy to Slide our coverage that
end impact GuardantXXX with of of are to for the upper now $X,XXX wins coverage range. ASPs the towards the We see $XX.XX to recent starting the
a September, our bottom this reimbursement be rate as In GuardantXXX lab Mike our will our progress in the CMS so LDT meaningful uplift increase year. to to to of process throughout the marks will on finalized, part next clinical milestone price that will cross impact If few more meaningfully ASPs expect under proposed the will see of year, far line. next shortly. Medicare a setting this $X,XXX significant for and top schedule late While months. fee this more a Guardant the share about ASP major have for we
to ultimate getting goal private coverage. testing the with payer working reimbursement of national also are biomarker We
MRG. providers We cases, both are made to selection inroads billion In California inactive and and share seeing are testing. to enacted date bills for population. the therapy New many these more, most Collectively, these rather here. builds To coverage support U.S. cover over XX pending. half biomarker have biomarker York Ohio important nearly states Two private recently, acquire
by American testing access comprehensive continue Cancer and passed support get to broaden will efforts to private these coverage. to to We expand Society bills to the in space more payer others biomarker
to continuing covered lives. and surpassed million TissueNext reimbursement for XXX with are recently progress we Lastly, the make
from coverage The inform test members. for recurrence we continuing and MRD, for Health relapse. we Geisinger received after disease on received therapy when to treatment We will more million physician adoption also of coverage Blue Cross additional Reveal forward to Plan, to surgery Guardant the be used about reimbursement previous curative Louisiana. wins. the Blue providing For Shield adjuvant and X.X covered coverage than from for Reveal of to or and decisions monitor This drive look builds or progression
In for review. liquid for data recent a Congress. at as was PEGASUS some discuss to of high-risk PEGASUS guidance patients. X relapse despite ESMO Slide postsurgical late-breaking to a treatment stage the data stage of on clinical XXX III with show abstract de-escalation Moving interim biopsy utility study the October, is biopsy Initial patients XX% that their results II cancer chemotherapy. liquid of surgery results colorectal initiation positive and had after released adjuvant cancer
relapse. XX% results experienced patients In addition, negative of with a the only
for ctDNA Reveal XX% treatment positive to provide are sensitive some to oncologists informed promising tool their ctDNA blood from chemotherapy suggesting suggest can make that after These of test that to efficacy patients. converted patients. outcomes improve our negative of patients and treatment results decisions Approximately a treatment help
expect rate this in full XXXX. We out study of
on With business. that, provide now over update screening to call I AmirAli will to an our turn the
